Trial Profile
A Study for Testing Safety and Efficacy of the Administration of Blood-Borne Autologous Endothelial Progenitor Cells to Alleviate Anginal Symptoms and Myocardial Ischemia in Patients With Severe Anginal Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2017
Price :
$35
*
At a glance
- Drugs ACP 01 (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Sponsors TheraVitae
- 21 May 2014 New trial record